Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low‐grade glioma
Open Access
- 19 December 2018
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (1) , 40-50
Abstract
In pediatric low‐grade gliomas not amenable to complete resection, various chemotherapy regimens are the mainstream of treatment. An excellent overall survival of these patients makes justification of the intensification of chemotherapy difficult and calls for the development of new strategies. Bevacizumab, a humanized monoclonal antibody directed against Vascular endothelial growth factor (VEGF), has been successfully used in combination with irinotecan in a number of adult and pediatric studies and reports. Fifteen patients at median age of 7 years old (range 3 months to 15 years) were treated with bevacizumab in combination with conventional low‐toxicity chemotherapy. The majority had chiasmatic/hypothalamic and midline tumors, seven had confirmed BRAF pathway alterations including neurofibromatosis type 1 (2). Fourteen patients had more than one progression and three had radiotherapy. No deaths were documented, PFS at 11 and 15 months was 71.5% ± 13.9% and 44.7% ± 17.6% respectively. At the end of follow‐up 40% of patients has radiologically stable disease, three patients progressed shortly after completion of bevacizumab and two showed mixed response with progression of cystic component. Rapid visual improvement was seen in 6/8 patients, resolution of endocrine symptoms in 2/4 and motor function improvement in 4/6. No relation between histology or BRAF status and treatment response was observed. Treatment‐limiting toxicities included grade 4 proteinuria (2) and hypertension (2) managed with cessation (1) and pausing of therapy plus antihypertensives (1). In conclusion, bevacizumab is well tolerated and appears most effective for rapid tumor control to preserve vision and improve morbidity.Keywords
This publication has 50 references indexed in Scilit:
- Irinotecan and bevacizumab in recurrent glioblastoma multiformeExpert Opinion on Pharmacotherapy, 2011
- Feasibility and efficacy of repeated chemotherapy for progressive pediatric low‐grade gliomasPediatric Blood & Cancer, 2010
- Outcome and prognostic features in pediatric gliomasCancer, 2009
- Phase II Trial of Conformal Radiation Therapy for Pediatric Low-Grade GliomaJournal of Clinical Oncology, 2009
- Objective response of multiply recurrent low‐grade gliomas to bevacizumab and irinotecanPediatric Blood & Cancer, 2009
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancerInternational Journal of Cancer, 1999
- Vascular endothelial growth factor and its receptorsProgress in Growth Factor Research, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Astrocytomas in childhood: A population-based studySurgical Neurology, 1985